Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

XL820

Known as: XL820-001 
An orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. XL820 binds to and inhibits the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Until the 1990s, cytotoxic chemotherapy has been the cornerstone of medical therapy for gastrointestinal (GI) cancers. Better… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
OBJECTIVE To investigate the drug targets related to Notch signaling pathway for glioma treatment. METHODS Gene expression… Expand
Is this relevant?
2007
2007
B237 Background: Ligand-independent activation of KIT is a critical factor in gastrointestinal stromal tumor (GIST) pathogenesis… Expand
Is this relevant?
2007
2007
B69 Background: XL820 is a small molecule inhibitor of several receptor tyrosine kinases (RTKs) with growth-promoting and… Expand
Is this relevant?
2006
2006
  • J. Ransom
  • Nature Biotechnology
  • 2006
  • Corpus ID: 30635855
Exelixis is reaping the benefits of a licensing and development deal with GlaxoSmithKline that gives the pharma partner an option… Expand
Is this relevant?
2006
2006
KINASE INHIBITOR, XL820, ADMINISTERED ORALLY TO PATIENTS WITH SOLID TUMORS Kyriakos P. Papadopoulos, Jordi Rodon, Alain Mita… Expand
Is this relevant?